Company
Syntax Bio
Syntax Bio's discovery platform overcomes the longstanding challenges in stem cell-derived therapies by directly controlling and accelerating cell differentiation.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Customers
- Biopharma discovery partnerships
Claim, correct or request removal
Record updated 28 September 2026
About
Syntax's proprietary Cellgorithm technology mimics human development to generate a wide diversity of functional cell types to enable new product opportunities.
Funding snapshot
- Total raised
- $15MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Series A2026-06-21
Funding rounds
- Series A
- 2026-06-21
- Round, 2024
- 2024-09-17
- Round, 2024
- $15M2024-02-17, Company stated
Products
- Other
- Cellgorithm
- Web
- Cellgorithm
Loading relationship preview